TRPM4 and prostate carcinoma: TRPM4 overexpression in lymph node carcinoma of the prostate cell line increased the total levels of β-catenin, proposing a role for TRPM4 channels in β-catenin oncogene signaling and again enforcing TRPM4 as a new potential target for future therapies in prostate cancer [204].